← All trials
NCT05113810
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 4, 2021
- Primary completion
- May 4, 2022
- Completion date
- May 4, 2022
- First posted
- Nov 9, 2021
- Last posted
- Nov 9, 2021
- Enrollment
- 110
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of JordanLead sponsor
- ACDIMA BiocenterCollaborator
- King Hussein Cancer CenterCollaborator
- Amman Pharmaceutical IndustriesCollaborator
- Government of JordanOverall official - principal investigator
- Sana Pharmaceutical IndustryCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.